Long-acting muscarinic antagonists.

Article Details

Citation

Copy to clipboard

Melani AS

Long-acting muscarinic antagonists.

Expert Rev Clin Pharmacol. 2015;8(4):479-501. doi: 10.1586/17512433.2015.1058154.

PubMed ID

26109098 [ View in PubMed

]

Abstract

Chronic obstructive pulmonary disease (COPD) is a major cause of death and disability worldwide. Inhaled bronchodilators are the mainstay of COPD pharmacological treatment. Long-acting muscarinic antagonists (LAMAs) are a major class of inhaled bronchodilators. Some LAMA/device systems with different characteristics and dosing schedules are currently approved for maintenance therapy of COPD and a range of other products are being developed. They improve lung function and patient-reported outcomes and reduce acute bronchial exacerbations with good safety. LAMAs are used either alone or associated with long-acting beta(2)-agonists, eventually in fixed dose combinations. Long-acting beta(2)-agonist/LAMA combinations assure additional benefits over the individual components alone. The reader will obtain a view of the safety and efficacy of the different LAMA/device systems in COPD patients.

DrugBank Data that Cites this Article

Drugs

Revefenacin

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Revefenacin	Muscarinic acetylcholine receptor (Protein Group)	Protein group	Humans	Yes	Antagonist	Details